- Case report
- Open Access
Prosthetic valve endocarditis caused by Candida lusitaniae, an uncommon pathogen: a case report
© Michel et al; licensee Cases Network Ltd. 2009
- Received: 12 August 2008
- Accepted: 22 January 2009
- Published: 14 May 2009
Candida lusitaniae was originally described as a human pathogen in 1979 and typically affects immunocompromised patients.
We describe a case of prosthetic valve endocarditis with Candida lusitaniae in an immunocompetent 62-year-old woman following aortic valve replacement. In vitro testing demonstrated that our isolate was sensitive to amphotericin B, caspofungin and fluconazole.
The infection was lethal despite aggressive medical and surgical management and sterilization of blood cultures. The outcome of our case illustrates the need to recognize Candida lusitaniae fungemia as a life-threatening infection in a patient with a prosthetic aortic valve.
- Minimal Inhibitory Concentration
- Aortic Valve Replacement
Candida species are the most frequent causes of fungal endocarditis. Mortality from Candida endocarditis has been reported at a rate of 50-80% . Candida albicans is the most frequently isolated species, followed by C. parapsilosis, C. glabrata and C. tropicalis. C. lusitaniae, originally described as a human pathogen in 1979, typically affects immunocompromised patients and accounts for less than 5% of all invasive Candida infections [2, 3]. Infections including meningitis, osteomyelitis and peritonitis have been reported, but the most common presentation of this pathogen is fungemia in patients undergoing chemotherapy for cancer -. Prosthetic valve endocarditis with this organism has been described only once previously . Although resistance to amphotericin B has been reported, a recent susceptibility study has shown that the majority of C. lusitaniae isolates are flucytosine resistant and amphotericin-B susceptible . In contrast, in vitro testing of the isolate in this case demonstrated sensitivity to amphotericin B, caspofungin and fluconazole.
A 62-year-old Caucasian woman presented with a two-month history of intermittent fever. Her past medical history included hypertension, dyslipidema, coronary artery disease and mild chronic kidney disease. She was found to have Enterococcus faecalis endocarditis of her native, bicuspid, aortic valve. She was treated with vancomycin, gentamicin and penicillin and subsequently underwent aortic valve replacement (AVR) with a Saint Jude valve in October of 2004. Her postoperative course was complicated by evacuation of a mediastinal hematoma, splenectomy and a partial colectomy with diverting colostomy for hemorrhagic colitis. The patient had been discharged and re-admitted multiple times and was ultimately transferred to the Oklahoma University Medical Center in May 2005.
Upon transfer, the patient complained of dyspnea, orthopnea and lower-extremity swelling. She was afebrile and hemodynamically stable. Her physical examination revealed jugular venous distention, a III/VI systolic murmur in the right second intercostal space, and bilateral lower-extremity edema to the knees. No peripheral stigmata of endocarditis were identified.
MICs and minimum fungicidal concentrations for Candida lusitaniae isolate from May 2005
Parameter, value (mcg/mL)
It remains unknown whether the source of our patient's fungemia was her abdominal surgery or a central venous catheter infection. Transesophageal echocardiography was helpful in identifying prosthetic valve infection and dysfunction. MIC testing of the initial fungal isolate demonstrated susceptibility to multiple antifungals. Potential biofilm formation on the prosthetic valve could have resulted in a discrepancy between the MIC derived from the blood isolate and the isolate at the site of infection, although the latter was not submitted for testing. Aggressive surgical management and antifungal treatment led to clearance of our patient's fungemia. Nevertheless, the infection resulted in a lethal outcome as in the previously described case . The shared outcome of our case with that of the previous case clearly illustrates the need to recognize Candida lusitaniae fungemia as a life-threatening infection in a patient with a prosthetic aortic valve.
We describe a case of prosthetic valve endocarditis with Candida lusitaniae following AVR in an immunocompetent patient. To our knowledge, this is only the second reported case of prosthetic valve endocarditis due to this uncommon Candida species. In vitro testing demonstrated that our isolate was sensitive to amphotericin B, caspofungin and fluconazole. As in the previously described case, this infection was lethal despite aggressive medical and surgical management and sterilization of blood cultures.
Written informed consent was obtained from the patient's next-of-kin for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
All authors have made substantial contributions to the case presentation and discussion, have been involved in drafting the manuscript or revising it critically for important intellectual content and have given final approval of the version to be published.
- Benjamin DK, Miro JM, Hoen B, Steinbach WJ, Fowler VG, Olaison L, Habib G, Abrutyn E, Perfect J, Zass A, Corey GR, Eykyn S, Thuny F, Jimenez-Exposito MJ, the Ice-md Study Group: Candida Endocarditis: Contemporary Cases from the International Collaboration of Infectious Endocarditis Merged Database. Scand J Infect Dis. 2004, 36: 453-455. 10.1080/00365540410020703.View ArticlePubMedGoogle Scholar
- Pappagianis D, Collins MS, Hector R, Remington J: Development of Resistance to Amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother. 1979, 16: 123-126.View ArticlePubMedPubMed CentralGoogle Scholar
- Ostrosky-Zeichner L, Pappas P: Invasive Candidiasis in the intensive care unit. Crit Care Med. 2006, 34: 857-862. 10.1097/01.CCM.0000201897.78123.44.View ArticlePubMedGoogle Scholar
- Hadfield TL, Smith MB, Winn RE, Rinaldi MG, Guerra C: Mycoses caused by Candida lusitaniae. Rev Infect Dis. 1987, 9: 1006-1012.View ArticlePubMedGoogle Scholar
- Blinkhorn RJ, Adelstein D, Spagnuolo PJ: Emergence of a New Opportunistic Pathogen, Candida lusitaniae. J Clin Microbiol. 1989, 27: 236-240.PubMedPubMed CentralGoogle Scholar
- Hawkins JM, Baddour LM: Candida lusitaniae Infections in the Era of Fluconazole Availability. Clin Infect Dis. 2003, 36: e14-e18. 10.1086/344651.View ArticlePubMedGoogle Scholar
- Wendt B, Hagland L, Razavi A, Rath R: Candida lusitaniae: an uncommon cause of prosthetic valve endocarditis. Clin Infect Dis. 1998, 26: 769-770. 10.1086/517126.View ArticlePubMedGoogle Scholar
- Favel A, Michel-Nguyen A, Datry A, Challier S, Leclerc F, Chastin C, Fallague K, Regli P: Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents. J Antimicrob Chemother. 2004, 53: 526-529. 10.1093/jac/dkh106.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.